Shots:

• Takeda is eligible to receive $10M up front in addition to $35M in Calithera Series A preferred stock and is eligible to receive clinical development- regulatory- and sales milestone for both programs along with royalties
• The acquisition will bolster Calithera’s precision oncology pipeline of clinical-stage targeted therapies i.e.- sapanisertib (TORC 1/2 inhibitor) and mivavotinib (SYK inhibitor). Both compounds as monothx. demonstrated clinical activity with the higher potential in biomarker-defined cancer-patient populations
• Additionally- Calithera plans to start a P-II study of sapanisertib for sq.NSCLC and mivavotinib for DLBCL with biomarker specific populations in 2022

  Ref: Globe Newswire | Image: Takeda